PCV13
PCV13 is a biological therapy with 23 clinical trials. Historical success rate of 94.4%.
Success Metrics
Based on 17 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
4
Mid Stage
13
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
94.4%
17 of 18 finished
5.6%
1 ended early
0
trials recruiting
23
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy
Fever After Simultaneous Versus Sequential Vaccination in Young Children
The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants
Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children
CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study
Clinical Trials (23)
Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy
Fever After Simultaneous Versus Sequential Vaccination in Young Children
The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants
Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children
CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study
Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines
A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months,7 Months-5 Years
A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine
Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels
Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)
Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma
Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia
PREVENTING PNEUMOcoccal Disease Through Vaccination (Study 2)
Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam
A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator
Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers
Pneumococcal Vaccines in Patients With Asthma
Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses
Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide
Burden of Hospitalized Pneumonia in Korea COPD Population
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 23